253 related articles for article (PubMed ID: 35197630)
1. Effective drug combinations in breast, colon and pancreatic cancer cells.
Jaaks P; Coker EA; Vis DJ; Edwards O; Carpenter EF; Leto SM; Dwane L; Sassi F; Lightfoot H; Barthorpe S; van der Meer D; Yang W; Beck A; Mironenko T; Hall C; Hall J; Mali I; Richardson L; Tolley C; Morris J; Thomas F; Lleshi E; Aben N; Benes CH; Bertotti A; Trusolino L; Wessels L; Garnett MJ
Nature; 2022 Mar; 603(7899):166-173. PubMed ID: 35197630
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on
Kim KO; Park WJ; Jung Y; Lee WS
J Chemother; 2020 Dec; 32(8):437-444. PubMed ID: 33052075
[TBL] [Abstract][Full Text] [Related]
3. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib.
Wang G; Huang Y; Wu Z; Zhao C; Cong H; Ju S; Wang X
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30674639
[TBL] [Abstract][Full Text] [Related]
4. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.
Allen JE; Gallant JN; Dicker DT; Amin S; Irby RB; Sharma AK; El-Deiry WS
PLoS One; 2013; 8(3):e59380. PubMed ID: 23555026
[TBL] [Abstract][Full Text] [Related]
5. L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells.
Jung SA; Lee DH; Moon JH; Hong SW; Shin JS; Hwang IY; Shin YJ; Kim JH; Gong EY; Kim SM; Lee EY; Lee S; Kim JE; Kim KP; Hong YS; Lee JS; Jin DH; Kim T; Lee WJ
Free Radic Biol Med; 2016 Jun; 95():200-8. PubMed ID: 27012422
[TBL] [Abstract][Full Text] [Related]
6. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models.
Jang HY; Kim DH; Lee HJ; Kim WD; Kim SY; Hwang JJ; Lee SJ; Moon DH
Biochem Pharmacol; 2019 Feb; 160():110-120. PubMed ID: 30579838
[TBL] [Abstract][Full Text] [Related]
8. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
[TBL] [Abstract][Full Text] [Related]
9. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
10. Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.
Dilly A; Honick BD; Lee YJ; Bartlett DL; Choudry HA
Cancer Med; 2020 Mar; 9(5):1753-1767. PubMed ID: 31958897
[TBL] [Abstract][Full Text] [Related]
11. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
Maitra R; Seetharam R; Tesfa L; Augustine TA; Klampfer L; Coffey MC; Mariadason JM; Goel S
Oncotarget; 2014 May; 5(9):2807-19. PubMed ID: 24798549
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
14. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Mayes PA; Degenhardt YY; Wood A; Toporovskya Y; Diskin SJ; Haglund E; Moy C; Wooster R; Maris JM
Int J Cancer; 2013 Feb; 132(3):E149-57. PubMed ID: 22948716
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs.
Duarte D; Cardoso A; Vale N
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299028
[TBL] [Abstract][Full Text] [Related]
19. Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer.
Park HJ; Park JB; Lee SJ; Song M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800074
[TBL] [Abstract][Full Text] [Related]
20. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
Bradshaw-Pierce EL; Pitts TM; Kulikowski G; Selby H; Merz AL; Gustafson DL; Serkova NJ; Eckhardt SG; Weekes CD
PLoS One; 2013; 8(3):e58089. PubMed ID: 23520486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
